老年人群中的临床试验:挑战与推进策略
该综述指出,历史上老年人常因年龄、多病共存和残疾被排除在药物临床试验之外,目前情况虽有改善但外部有效性仍受质疑。试验参与者通常比老年门诊患者更简单,招募和保留老年参与者是特殊挑战,需多通道招募、代理签署知情同意及专门支持。非药物试验盲法常不完美,干预需足够强度和时长,结局指标应对老年人相关且敏感,缺失值常见需在设计时考虑。尽管有障碍,老年医学RCT必须推进以提供可靠证据。
要点
- 老年人常因年龄、多病共存和残疾被排除在药物试验外,试验外部有效性仍受质疑。
- 招募和保留老年参与者需多通道招募、代理知情同意及对衰弱多病残疾者的专门支持。
- 非药物试验盲法常不完美,干预需足够强度和时长,结局指标应对老年人相关且敏感。
核心结论
- 尽管存在招募保留困难、盲法不完美、缺失值等障碍,老年医学RCT必须推进,以为老年人的治疗管理和照护提供可靠证据。
研究设计与样本
- 本文为综述,讨论随机对照试验(RCT)在老年人群中的实施问题,未报告具体检索范围或样本量。
主要发现
- 历史上老年人常因年龄、多病共存和残疾被排除在药物临床试验之外,目前情况改善但许多试验的外部有效性仍受质疑。
- 试验参与者通常比老年门诊患者更简单,招募和保留老年参与者是临床试验的特殊挑战。
- 成功招募需要多通道,尤其衰弱、多病共存和残疾者需要支持才能参与;认知下降常见,常需代理签署知情同意。
- 老年人可能在试验中生病或疲劳,需要特殊支持和有同理心的研究人员以成功保留参与者。
- 非药物试验中盲法不完美常不可避免,干预必须设计得足够强度和时长以显示组间差异,对照参与者仍须接受最佳常规照护。
关键数值与推荐
- 结局指标应对老年人相关、对变化敏感并针对试验特定人群。
- 测量中的缺失值常见,设计试验时应予以考虑。
临床怎么用
- 在老年医学临床试验中应采用多通道招募,并为衰弱、多病共存和残疾参与者提供参与支持。
- 对认知下降者可使用代理签署知情同意,并安排有同理心的研究人员以促进保留。
- 设计非药物试验时需考虑盲法不完美,确保干预强度和时长足够,并选择对老年人相关且敏感的结局指标。
- 设计试验时应预先考虑缺失值问题并制定应对策略。
局限性
- 本文为综述,未报告系统检索策略、纳入研究数量或定量合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomised controlled trials (RCTs) usually provide the best evidence for treatments and management. Historically, older people have often been excluded from clinical medication trials due to age, multimorbidity and disabilities. The situation is improving, but still the external validity of many trials may be questioned. Individuals participating in trials are generally less complex than many patients seen in geriatric clinics. Recruitment and retention of older participants are particular challenges in clinical trials. Multiple channels are needed for successful recruitment, and especially individuals experiencing frailty, multimorbidity and disabilities require support to participate. Cognitive decline is common, and often proxies are needed to sign informed consent forms. Older people may fall ill or become tired during the trial, and therefore, special support and empathic study personnel are necessary for the successful retention of participants. Besides the risk of participants dropping out, several other pitfalls may result in underestimating or overestimating the intervention effects. In nonpharmacological trials, imperfect blinding is often unavoidable. Interventions must be designed intensively and be long enough to reveal differences between the intervention and control groups, as control participants must still receive the best normal care available. Outcome measures should be relevant to older people, sensitive to change and targeted to the specific population in the trial. Missing values in measurements are common and should be accounted for when designing the trial. Despite the obstacles, RCTs in geriatrics must be promoted. Reliable evidence is needed for the successful treatment, management and care of older people.
引用
- Pitkala KH, Strandberg TE. Clinical trials in older people. Age Ageing. 2022. PMID: 35526845. doi:10.1093/ageing/afab282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。